
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses the FDA-approved therapy tivozanib (Fotivda) for patients with relapsed or refractory advanced renal cell carcinoma, including ongoing trials further exploring the agent.